
    
      Participants were randomized in a 1:1 ratio to receive a single dose of MenACYW conjugate
      vaccine or MenomuneÂ® - A/C/Y/W-135 on Day 0 (Visit 1).

      Participants underwent immunogenicity assessment at baseline (pre-vaccination) and at 30 to
      44 days post-vaccination and were also evaluated for safety up to Day 180 post-vaccination.
    
  